.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
QuintilesIMS
Citi
Mallinckrodt
Queensland Health
US Army
Fish and Richardson
Healthtrust
Novartis
Colorcon

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Compositions of estrogen-cyclodextrin complexes
Abstract: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and .beta.-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
Inventor(s): Backensfeld; Thomas (Berlin, DE), Heil; Wolfgang (Berlin, DE), Lipp; Ralph (Berlin, DE)
Assignee: Bayer Schering Pharma AG (Berlin, DE)
Filing Date:Dec 04, 2006
Application Number:11/607,919
Claims:1. A daily dosage unit for inhibiting ovulation comprising: i) micronized drospirenone and a complex between ethinyl estradiol and a cyclodextrin, wherein drospirenone is present in an amount of from 2 mg to 4 mg, and wherein ethinyl estradiol is present in an amount of from 0.01 mg to 0.05 mg; and ii) one or more excipients(s).

2. The dosage unit according to claim 1, wherein ethinyl estradiol is present in an amount of from 0.015 mg to 0.04 mg.

3. The dosage unit of claim 1, wherein the ethinyl estradiol is present in an amount of from 0.015 mg to 0.03 mg.

4. The dosage unit of claim 1, wherein drospirenone is present in an amount of from 2.5 mg to 3.5 mg.

5. The dosage unit of claim 1, wherein drospirenone is present in an amount of about 3 mg.

6. The dosage unit of claim 1, wherein the cyclodextrin is selected from the group consisting of .alpha.-cyclodextrin, .beta.-cyclodextrin, .gamma.-cyclodextrin and alkylated or acylated derivatives thereof.

7. The dosage unit of claim 1, wherein the cyclodextrin is selected from the group consisting of .beta.-cyclodextrin and alkylated or acylated derivatives thereof.

8. The dosage unit of claim 1, wherein the cyclodextrin is .beta.-cyclodextrin.

9. The dosage unit of claim 1, wherein the complex between ethinyl estradiol and a cyclodextrin is micronized.

10. The dosage unit of claim 1, wherein the micronized drospirenone and the complex between ethinyl estradiol and a cyclodextrin are in the form of a granulate preparation having a relative humidity of at most 60%, as determined at a temperature between 20.degree. C. and 40.degree. C.

11. The dosage unit of claim 10, wherein the granulate preparation has a relative humidity of at most 55%, as determined at a temperature between 20.degree. C. and 40.degree. C.

12. The dosage unit according to claim 1, comprising, at most, 2% w/w of polyvinylpyrrolidone.

13. The dosage unit according to claim 1, comprising, at most, 1% w/w of polyvinylpyrrolidone.

14. The dosage unit according to claim 1, further comprising an antioxidant.

15. The dosage unit according to claim 1, wherein the dosage unit is in the form of a tablet, capsule or sachet.

16. The dosage unit according to claim 1, wherein the dosage unit is in the form of a tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Healthtrust
McKinsey
Fish and Richardson
Mallinckrodt
Teva
US Army
Deloitte
Novartis
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot